Scenic Biotech is a brand specializing in evolution-inspired medicine for rare diseases. Their main focus is on identifying genetic modifiers for drug intervention. Genetic modifiers, also known as disease suppressors, are genes that suppress or completely block the effect of disease-causing mutated genes.

Founded in 2017 as a spin-out of the Netherlands Cancer Institute and Oxford University, Scenic has built a strong intellectual property portfolio through licensing from academic partners and their own strategic initiatives. Led by a team of ambitious leaders in genomics research, including their CEO Oscar Izeboud and CMO Jens Würthner, the company is dedicated to making advancements in drug discovery and early-stage development. With expertise in various areas, such as legal affairs, drug discovery, and portfolio strategy, Scenic Biotech is committed to providing innovative solutions for rare diseases